2009;151:297 305. 418. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14 21. 419. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710 1716. 420. Eckman MH, Wong LK, Soo YO, Lam W, Yang SR, Greenberg SM, Rosand J. Patient-specific decision-making for warfarin therapy in non- valvular atrial fibrillation: how will screening with genetics and imaging help? Stroke. 2008;39:3308 3315. 421. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hem- orrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689 2696. 422. Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A, Woodward M, MacMahon S, Neal B; PROGRESS Collaborative Group. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient isch- emic attack. Stroke. 2005;36:2164 2169. 423. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M; Writing Committee of the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke. 2004;35:116 121. 424. Lip GY, Frison L, Grind M; SPORTIF Investigators. Effect of hyper- tension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752 759. 425. Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE; Anticoagulation Forum. Delivery of optimized anticoagu- lant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008;42:979 988. 426. 